Michael Schmitt

Full Professor

UniversitätsKlinikum Heidelberg

Germany

Research Interests

Explore related searches

Professors in Germany Professors in Immunology Immunology professors in Germany

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

About

Michael Schmitt is a Full Professor at UniversitätsKlinikum Heidelberg in Germany. His research areas include T-Cell receptor therapies, chronic COVID-19 treatments in hematologic malignancies, and immunotherapy strategies for various neoplasms. He has contributed to the understanding of CAR-T cell functionality, leukocyte treatment approaches for acute myeloid leukemia, and the development of peptide vaccinations for cytomegalovirus-related diseases.

Articles (14)

Year:

2025

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Year:

2021

Collaborators (2)

Leoni Kunz-Schughart

Prof.

Technische Universität Dresden

GERMANY

View details

Robert Zeiser

Director Div. of Tumor immunology/Professor

University Medical Center Freiburg

GERMANY

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Michael Schmitt

Research Interests

Explore related searches

Contact this professor

About

Articles (14)

First-in-Human Study of MDG1011, a TCR-T Therapy Directed Against HLA-A*02:01-Restricted PRAME Antigen for High-Risk Myeloid and Lymphoid Neoplasms

Treatment of chronic COVID‐19 with convalescent/postvaccination plasma in patients with hematologic malignancies

In Vitro Functionality and Endurance of GMP-Compliant Point-of-Care BCMA.CAR-T Cells at Different Timepoints of Cryopreservation

Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma

Symptomatic Patients with Hyperleukocytic FLT3-ITD Mutated Acute Myeloid Leukemia Might Benefit from Leukapheresis

Cure of intravascular NK/T-cell lymphoma of the central nervous system by allogeneic hematopoietic cell transplantation

HDAC Inhibition for Optimized Cellular Immunotherapy of NY-ESO-1-Positive Soft Tissue Sarcoma

Common T-Cell-Receptor Motifs and Features in Patients with Cytomegalovirus (CMV)-Seronegative End-Stage Renal Disease Receiving a Peptide Vaccination against CMV

Comparison of FACS and PCR for Detection of BCMA-CAR-T Cells

Intracellular Amplifiers of Reactive Oxygen Species Affecting Mitochondria as Radiosensitizers

Sensitivity and Specificity of CD19.CAR-T Cell Detection by Flow Cytometry and PCR

Infection Complications after Lymphodepletion and Dosing of Chimeric Antigen Receptor T (CAR-T) Cell Therapy in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia or B Cell Non-Hodgkin Lymphoma

The impact of allogeneic hematopoietic cell transplantation on the mortality of poor-risk non-Hodgkin lymphoma: an intent-to-transplant analysis

Comments on “Cost of decentralized CAR T cell production in an academic non‐profit setting”

Collaborators (2)

Leoni Kunz-Schughart

Robert Zeiser

Make your next move.